In the News & Media.


In the News


Media

Efti: A Soluble LAG-3 Protein & MHC Class II Agonist that Unlocks a Broad Anticancer Immune Response

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 31 October 2023 - CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Congress.

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 19 May 2023 - Executive Director and CEO Marc Voigt discusses the significance of recent announcements on the back of a recent surge in trading volume.

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 01 Mar 2023 - Executive Director and CEO Marc Voigt discusses data from SITC, the strategy to take Efti to market and milestones for 2023.

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 28 Nov 2022 - CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company's portfolio of therapies, encouraging data from the 2022 SITC conference and the outlook for 2023.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 12 Oct 2022 - CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company's new Phase 2 trial in soft tissue sarcoma and the outlook ahead.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 06 Apr 2022 - From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep's Executive Director and CEO, Marc Voigt.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 30 Mar 2022 - Executive Director and CEO Marc Voigt discusses the company's LAG-3-related therapies, outlining future plans and expected data readouts for Immutep's lead drug, eftilagimod alpha.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 30 Mar 2022 - Executive Director and CEO Marc Voigt discusses encouraging results in second-line non-small cell lung cancer.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 28 Mar 2022 - Executive Director and CEO, Marc Voigt speaks to Naureen Quibria, PhD. of Maxim Group about LAG-3 and an overview of the company outlining future plans

Frédéric Triebel, MD, PhD, Immutep Paris, France, discusses the TACTI-002 and TACTI-003 trials - Eftilagimod alpha for metastatic head and neck squamous cell carcinoma

Frédéric Triebel, MD, PhD, Immutep Paris, France, discusses the final results from the Phase IIb AIPAC trial of eftilagimod alpha vs placebo with chemo for HR+ HER2- MBC

Marc Voigt, Chief Executive Officer of Immutep (ASX:IMM; NASDAQ: IMMP) presents at the Bell Potter Healthcare Conference 2021

Listen to the Spotify Podcast Interview of Dr. Frederic Triebel by Neil Canavan “Immutep: No Longer Left Behind: LAG-3 Hits the Clinical (Late) Stage “

Immutep Limited (ASX: IMM; NASDAQ: IMMP), 18 Aug 2021 - Bell Direct’s Jessica Amir speaks to Immutep's Executive Director and CEO, Marc Voigt

Immutep Limited (ASX: IMM; NASDAQ: IMMP) 04 May 2021 - CEO and Executive Director Marc Voigt speaks with Share Cafe's Tim McGowen about Immutep’s leading position within the LAG-3 competitive landscape

Finance News Network Interview, 29 Mar 2021, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial

Benzinga Biotech Small Cap Conference with CEO Marc Voigt, Wednesday, 24 March 2021, Immutep Limited (ASX: IMM, NASDAQ:IMMP) - CEO Presentation

Ausbiz Interview with CEO Marc Voigt, 17 March 2021, Immutep Limited (ASX: IMM; NASDAQ:IMMP) - Immutep Collaborates with US-based Merck & Co

Finance News Network Interview, 27 Jan 2021, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO and Executive Director Marc Voigt analyses December's breast cancer data, and provides an update on efti's position and outlook

Immutep: fighting the good fight, 17 December 2020 - CEO Marc Voigt speaks with Share Cafe’s Tim McGowen about the company’s operations, clinical trials and future developments